Press Releases
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Corbus Pharmaceuticals Announces Pricing of Public Offering
Corbus Pharmaceuticals Announces Proposed Public Offering
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
